NAL 3210
Alternative Names: NAL-3210Latest Information Update: 28 May 2024
At a glance
- Originator NAL Pharma
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Onychomycosis
Most Recent Events
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Onychomycosis in Unknown (Topical, Liquid)
- 26 May 2022 NAL 3210 is still in clinical trials in Onychomycosis (NAL Pharma pipeline, May 2022)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Onychomycosis in Unknown (Topical, Liquid)